All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
11 - 20 of 53 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.
First results for IV VSV-GP (BI 1831169) in patients with advanced solid tumors from the 1456-0001 study
Author(s): Oliva et al.
Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumors: updated data
Author(s): Wermke et al.
Population Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events During T cell Engager Therapy
Author(s): Kluwe et al.
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
DAREON®-7: a Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Capdevila et al.
Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
Author(s): Lucas et al.
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Author(s): Calvo et al.
Open-label, Phase I dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
Author(s): Gutierrez et al.
![Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3](/events/inoncology-congresses/sites/default/files/2025-08/phase-1-bi-764532-dll3-dose-escalation.png)
Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas expressing DLL3
Author(s): Mazières et al.